Those with PCOS may be more likely to experience this type of cycle change, which is also in line with previous research where GLP-1 medications have shown some promise for improving menstrual cycle regularity in women with PCOS
In recent years, Novo Nordisks injectable Wegovy and Lillys Zepbound have revolutionized obesity treatment globally and in the US, where 100 million people have the chronic disease
Both are synthetic peptides designed to mimic and amplify the effects of naturally occurring incretin hormones, but they activate a different number of receptors
This distinction matters, especially when information online presents it as readily accessible or interchangeable with other treatments
Energy levels and cognitive function frequently receive a boost as well
One review captured the fields frustration with the title: Great expectations, but with limited success. Two drugs, two philosophies and very different risk profiles The race to combine a myostatin inhibitor with a GLP-1 drug now has two leading candidates, and they represent fundamentally different strategies